Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07682454 · ClinicalTrials.gov registry record · Phase 2
Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
A Phase 2 study, sponsored by University of California, San Francisco.
- Not yet
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT07682454 is a Phase 2 study that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 50 participants.
The verdict
NCT07682454, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, San Francisco.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a single-arm, open-label, single-center, first-in-human feasibility study evaluating parenchymal blood volume (PBV) imaging as a tool to dynamically assess perfusional changes in hepatocellular carcinoma (HCC) potentiated by intra-arterial administration of nitroglycerin.
Interventions
- OTHER Medical Record Review
- DRUG Nitroglycerin
- PROCEDURE Parenchymal Blood Volume (PBV) Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2030-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07682454
The ClinicalTrials.gov registry entry for NCT07682454 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Medical Record Review is the first listed.
NCT07682454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07682454 about?
NCT07682454 is a clinical study titled "Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin". This is a single-arm, open-label, single-center, first-in-human feasibility study evaluating parenchymal blood volume (PBV) imaging as a tool to dynamically assess perfusional changes in hepatocellular carcinoma (HCC) potentiated by intra-arterial administration of nitroglycerin.
What is the current status of trial NCT07682454?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-08-01. Estimated completion is 2030-02-01.
What interventions are being tested in trial NCT07682454?
The interventions under investigation include: Medical Record Review (OTHER), Nitroglycerin (DRUG), Parenchymal Blood Volume (PBV) Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT07682454?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.